Singapore, May 7 -- Waiv, formerly Owkin Dx, a Paris-based company catalysing artificial intelligence (AI) precision testing, has entered a collaboration with Japan-based Daiichi Sankyo to lead digital pathology biomarker discovery for an antibody-drug conjugate (ADC) programme.

With deep expertise across diverse pathology and multimodal data, and a global data network spanning academic institutions, hospitals, and laboratories, Waiv has a proven track record delivering AI-powered biomarker solutions across the full drug development lifecycle.

Under the collaboration, Waiv will apply its end-to-end computational pathology platform to early phase data. This includes tumour microenvironment (TME) analysis across both hematoxylin and eosin...